AVROBIO
One Kendall Square
Building 300, Suite 201
Cambridge
MA
02139
United States
Tel: 617.914.8420
Website: https://avrobio.com/
21 articles with AVROBIO
-
Clinical Catch-Up: October 7-11
10/14/2019
It was a busy week for clinical trial announcements. Here’s a look. -
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
10/8/2019
Investigational Therapy Designed to Engineer Patients’ Own Stem Cells to Produce Essential Protein
-
AVROBIO, Inc. to Present at Chardan’s 3rd Annual Genetic Medicines Conference
10/3/2019
AVROBIO, Inc. announced that Geoff MacKay, President and CEO of AVROBIO, will present at Chardan’s 3rd Annual Genetic Medicines Conference on Monday, October 7, 2019.
-
AVROBIO, Inc. to Present at Upcoming Investor Conferences - Aug. 29, 2019
8/29/2019
AVROBIO, Inc. announced that members of its senior management team are scheduled to participate in five upcoming investor conferences.
-
AVROBIO Appoints Georgette Verdin as Chief Human Resources Officer
8/16/2019
AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO).
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug. 12, 2019
8/12/2019
AVROBIO, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018 Stock Option and Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
AVROBIO Reports Second Quarter 2019 Financial Results and Provides Business Update
8/8/2019
AVROBIO, Inc. reported financial results for the second quarter ended June 30, 2019 and provided a business update.
-
AVROBIO, Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference
8/6/2019
AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City.
-
AVROBIO Announces Pricing of Underwritten Public Offering of $120.25 Million of Common Stock
7/17/2019
AVROBIO, Inc., a Phase 2 clinical-stage gene therapy company, announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $18.50 per share.
-
AVROBIO Announces Proposed Public Offering of Common Stock
7/16/2019
AVROBIO, Inc. announced that it intends to offer and sell, subject to market and other conditions, $100.0 million of its common stock in an underwritten public offering.
-
AVROBIO Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease
7/15/2019
AVROBIO, Inc. announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease.
-
AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease
4/29/2019
The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients
-
AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy
4/26/2019
AVROBIO, Inc. announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy.
-
AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update
3/25/2019
Introduced plato™ platform for worldwide gene therapy commercialization, to be incorporated in AVROBIO-sponsored clinical trials in 2019
-
AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease
2/6/2019
All patients with reported data exhibit AGA enzyme activity above the diagnostic range for males with classic Fabry disease after receiving AVR-RD-01, including at 22 months for Patient 1 in the Phase 1 study
-
Shares of Cambridge, Mass.-based Avrobio plunged more than 50 percent on Monday after the company provided an updated look at its gene therapy for Fabry disease that showed promise for the treatment, but also raised some concern for investors.
-
It’s been a pretty good year for mergers and acquisitions in the biopharma industry. But the landscape for IPOs has been excellent as well, particularly in Massachusetts, which has recorded 13 IPOs since the beginning of the year.
-
Autolus Brings in $150 Million in IPO, Continues Strong Investment Trend for Biotechs This Week
6/22/2018
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month. -
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
-
Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals
5/29/2018
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.